Recent Research Analysts’ Ratings Updates for Relay Therapeutics (RLAY)

Relay Therapeutics (NASDAQ: RLAY) has recently received a number of price target changes and ratings updates:

• 7/22/2026 – Relay Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/21/2026 – Relay Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $22.00 to $31.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 7/8/2026 – Relay Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
• 7/6/2026 – Relay Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/6/2026 – Relay Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the transaction, the chief financial officer directly owned 177,461 shares in the company, valued at approximately $3,011,513.17. The trade was a 51.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Donald A. Bergstrom sold 93,456 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.94, for a total transaction of $1,583,144.64. Following the sale, the insider directly owned 418,557 shares of the company’s stock, valued at approximately $7,090,355.58. The trade was a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 422,912 shares of company stock valued at $7,378,537. 5.04% of the stock is currently owned by insiders.

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.